The Medical Letter on Drugs and Therapeutics
Ezogabine (Potiga) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ezogabine (ee-ZOE-ga-been; Potiga – GSK/Valeant) for oral adjunctive treatment of partial-onset seizures in adults. Ezogabine is available in Europe as retigabine (Trobalt).1

DRUGS FOR PARTIAL SEIZURES — Partial seizures may require treatment with multiple drugs. New drugs for epilepsy are often initially approved by the FDA only as adjunctive therapy for partial seizures, but many are used subsequently to treat generalized seizures as well.2

MECHANISM OF ACTION — Ezogabine is a potassium channel facilitator; it activates KCNQ channels, reducing the degree of depolarization needed to open the channel. As a result, the channel opens faster and stays open longer, slowing repetitive firing in the brain.3 Ezogabine has been effective in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ezogabine (Potiga) for Epilepsy
Article code: 1397a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian